Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA)

被引：0
|
作者：
Llibre, J. M. [1 ]
Alves, C. [2 ]
Cheng, C-Y [3 ,4 ]
Osiyemi, O. [5 ]
Galera, C. [6 ]
Hocqueloux, L. [7 ]
Maggiolo, F. [8 ]
Degen, O. [9 ]
Blair, E. [10 ]
Wynne, B. [10 ]
Oyee, J. [11 ]
Underwood, M. [10 ]
Curtis, L. [11 ]
Bontempo, G. [10 ]
van Wyk, J. [12 ]
机构：
[1] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[2] Univ Fed Bahia, Salvador, BA, Brazil
[3] Minist Hlth & Welf, Taoyuan Gen Hosp, Taoyuan, Taiwan
[4] Natl Yang Ming Univ, Sch Publ Hlth, Taipei, Taiwan
[5] Triple O Res Inst PA, W Palm Beach, FL USA
[6] Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain
[7] Ctr Hosp Reg Orleans, Orleans, France
[8] ASST Papa Giovanni XXIII, Bergamo, Italy
[9] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[10] ViiV Healthcare, Res Triangle Pk, NC USA
[11] GlaxoSmithKline, Uxbridge, Middx, England
[12] ViiV Healthcare, Brentford, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OALB0303
引用
收藏
页码：13 / 14
页数：2
相关论文
共 29 条
  • [1] Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)
    Van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria-Claudia
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    Wynne, Brian
    Aboud, Michael
    Smith, Kimberly Y.
    HIV MEDICINE, 2021, 22 : 28 - 28
  • [2] Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)
    van Wyk, J.
    Ajana, F.
    Bisshop, F.
    De Wit, S.
    Osiyemi, O.
    Portilla, J.
    Routy, J.
    Wyen, C.
    Ait-Khaled, M.
    Nascimento, M.
    Pappa, K.
    Wang, R.
    Wright, J.
    Wynne, B.
    Aboud, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 14 - 15
  • [3] Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 48 weeks: subgroup analyses from the TANGO study
    Ait-Khaled, M.
    Nascimento, M. C.
    Pappa, K. A.
    Wang, R.
    Wright, J.
    Tenorio, A. R.
    Wynne, B.
    Aboud, M.
    Gartland, M.
    van Wyk, J.
    HIV MEDICINE, 2019, 20 : 20 - 20
  • [4] Switching to DTG/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses
    Taylor, S.
    Andrade-Villanueva, J. F.
    Kaplan, R.
    Nahass, R.
    Hocqueloux, L.
    Scholten, S.
    Di Giambenedetto, S.
    Galera, C.
    Blair, L.
    Wynne, B.
    Oyee, J.
    Underwood, M.
    Curtis, L.
    Bontempo, G.
    van Wyk, J.
    HIV MEDICINE, 2021, 22 : 129 - 129
  • [5] Switching to DTG+3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study)
    van Wyk, J.
    Ajana, F.
    Bisshop, F.
    De Wit, S.
    Osiyemi, Y.
    Portilla, J.
    Routy, J. -P.
    Wyen, C.
    Ait-Khaled, M.
    Nascimento, M.
    Pappa, K.
    Wang, R.
    Wright, J.
    Tenorio, A. -R.
    Wynne, B.
    Aboud, M.
    Gartland, M.
    Smith, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 102 - 103
  • [6] Switching to DTG/3TC fixed-dose combination (FDC) is noninferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks: TANGO study
    van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria-Claudia
    Pappa, Keith
    Wang, Ruolan
    Wright, Jonathan
    Wynne, Brian
    Aboud, Michael
    Smith, Kimberly
    Rubach, Martin
    INFECTION, 2021, 49 (SUPPL 1) : S13 - S13
  • [7] Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study
    Wang, R.
    Horton, J.
    Wright, J.
    Razeek, R.
    Ait-Khaled, M.
    Nascimento, M. C.
    Tenorio, A. R.
    Underwood, M.
    HIV MEDICINE, 2019, 20 : 95 - 95
  • [8] Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study
    van Wyk, J.
    Ait-Khaled, M.
    Santos, J.
    Scholten, S.
    Wohlfeiler, M.
    Ajana, F.
    Jones, B.
    Nascimento, M. C.
    Tenorio, A.
    Smith, D.
    Wright, J.
    Wynne, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 27 - 27
  • [9] Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
    Kumar, Princy
    Clarke, Amanda E.
    Jonsson-Oldenbuettel, Celia
    Deltoro, Miguel Garcia
    Di Giambenedetto, Simona
    Brites, Carlos
    Hocqueloux, Laurent
    Lu, Po-Liang
    Oyee, James
    Oglesby, Alan
    Wynne, Brian
    Jones, Bryn
    Evitt, Lee A.
    Fox, Dainielle
    Kisare, Michelle
    Priest, Julie
    AIDS AND BEHAVIOR, 2025, 29 (01) : 235 - 245
  • [10] Patient-reported outcomes after switching to a 2-drug regimen of fixed-dose combination dolutegravir/lamivudine: 48-week results from the SALSA Study
    Kumar, P.
    Clarke, A. E.
    Jonsson-Oldenbuttel, C.
    Garcia Deltoro, M.
    Di Giambenedetto, S.
    Brites, C.
    Hocqueloux, L.
    Lu, P-L
    Oyee, J.
    Oglesby, A.
    Priest, J.
    Blair, E.
    Wynn, B.
    Gordon, L. A.
    Letang, E.
    van Wyk, J.
    Evitt, L. A.
    ANTIVIRAL THERAPY, 2021, 26 : 40 - 41
123